enlightenVue™ founders have a broad range of complementary business expertise that provide for a well-rounded foundation for the company.
Leadership

Bob Kucharski
Chairman of the Board

Alan Lucas
Director I CEO enlightenVue
LinkedIn

Doug Jones
Commercialization
LinkedIn
Clinical Leadership

Desmond Birkett, MD
Beth Israel Lahey Health – General Surgery

Craig Derkay, MD
Eastern Virginia Medical School – Pediatric Otolaryngology Surgeon

Naomi Garland, MD
Cambridge Health Alliance – Department of Surgery

Lee Gorden, MD
Vanderbilt University Medical Center – Hepatobiliary Surgeon

David Feller-Kopman, MD
Dartmouth Hitchcock Medical Center – Pulmonologist

John McKee III, MD
Singing River Health System – Gastroenterologist
Board of Directors

Bob Kucharski
Chairman of the Board
Bob founded a real estate company with a focus on Shopping Center Development. Awarded the 2004 Phoenix Award for the redevelopment of a brownfield site which was referred to as the Brownfield equivalent of Hollywood’s Oscar.
He sold the company after 25 years and then co-founded a boutique investment banking venture. During that time recognized the market opportunity for a small disposable micro endoscope and brought the enlightenVue team together to pursue that endeavor.
Bob’s core strengths are developing high-preforming teams which result in operational excellence.

Gabriele Brambilla
Director I CEO Alira Health
Under Gabriele’s leadership, Alira Health, which was an early investor in enlightenVue, has grown from a boutique consultancy of fewer than 30 employees to a global enterprise with over 800 team members. He has raised more than $100 million in capital and serves on the board of MassMEDIC and other MedTech organizations.

Richard Gentile
Director
Richard has held several key senior sales and marketing leadership roles, at Olivetti and General Electric, as well as 25+ years of experience in land development and new construction projects. Most recently, Richard has served for more than a decade on the Board of Directors for Guilford Savings Bank in Guilford, Connecticut. He utilizes a blend of corporate leadership, industry expertise, and board service to promote strategic growth and drive operational excellence.

Alan Lucas
Director I CEO enlightenVue
Alan has served in senior business development and marketing positions at development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful fund raising through IPOs, private placements, and cross border M&A transactions. His experience includes work at Alira Health, Navigation Sciences, Simplicity Orthopedics, ABIOMED, Implant Sciences, Kirschner Orthopedics and ACUFEX MicroSurgical.

John McKee III, MD
Director I Gastroenterologist
Dr. John McKee III brings more than 35 years of experience in gastroenterology, with an extensive background in postgraduate research and clinical studies. He has contributed to over 20 published works focused on gastrointestinal endoscopy, including significant studies involving MR cholangiopancreatography and endoscopic retrograde cholangiopancreatography. John was a fellow at Harvard medical school, Beth Israel Deaconess advanced therapeutic endoscopy Fellowship program. In addition, he has been invited to serve as faculty for numerous GI courses focused on advanced therapeutic endoscopy and that he has been involved with cholangioscopy and pancreatoscopy for 30 years. During this period he has served as a professional consultant helping to improve endoscopy equipment by combining vast clinical experience with a technical background focused on enhanced safety and capability. Board Certified in both Gastroenterology and Internal Medicine by the American Board of Internal Medicine, Dr. McKee served and completed his term as President of the MSMA Gastroenterology Society. He is also a partner at the Digestive Health Center in Ocean Springs, Mississippi.
John’s Professional goal: To provide our next generation of physician endoscopists with tools to diagnose cancer of the pancreas and biliary tract at the earliest stages and potentially improve clinical outcomes.



